SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (240)11/6/2002 12:00:22 PM
From: keokalani'nui  Read Replies (1) | Respond to of 824
 
alxn data is very strong. But 10 P1 patients might represent the universe in the UK.

Would anyone mind looking at the velc*de abstract? Did RR come down from promised at oncology preview (or did I transpose the % protein reduction with 'tumor response'? And does it look like maybe more pts than expected moved to dex? Without a subsequent dex-only arm, what good will dex+ data be?

Or is my mind victim of a bear market?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News